Basket trials are designed to test therapies that target a specific genetic mutation found in the tumor, regardless of tumor histology. This emerging trend raises a number of key questions for the industry.
Recommendations focus on ways to prevent opioid misuse and reduce risk of addiction.
FDA’s plan to evaluate gene therapies’ impact on surrogate end points is amping up concerns among payers. Here’s why
The International Rare Diseases Research Consortium hopes to develop 200 new drugs for rare diseases by 2020, and it seems as if things are better than on track.
Some of the most amazing things are happening in the delivery of medical care these days. Surgical techniques, new devices, drugs, and diagnostics can treat and cure many medical conditions.
Congress recently began hearings on proposals to combat opioid abuse. Our policy analyst weighs in.
Two health plans are sharing the wealth—in this case, drug discounts from manufacturers—with consumers at point of sale.
How skipping industry acronyms and jargon and using simple terminology will eliminate confusion and misinterpretation.
A Surescripts survey reveals the need for more interoperable access to patient data in three major areas.
An ONC report finds that more patients are engaged with their health records. Here’s why.